本文選題：依維莫司 + 佐他莫司�。� 參考：《廣西醫(yī)科大學》2017年碩士論文

【摘要】：目的:系統(tǒng)評價依維莫司藥物涂層支架(Everolimus-eluting stents,EES)與佐他莫司藥物涂層支架(Zotarolimus-eluting stents,ZES)治療冠心病的安全性與有效性。方法:計算機檢索PubMed、Web of science、The Cochrane Library、中國維普(VIP)、中國知網(wǎng)(CNKI)、中國生物醫(yī)學(CBM)、萬方數(shù)據(jù)庫,納入關于比較EES和ZES治療冠心病患者的隨機對照試驗(Randomized controlled trial,RCTs)。由2位評價員獨立評價并提取數(shù)據(jù),按照Cochrane系統(tǒng)評價員手冊(5.1.0版)評價納入研究的質(zhì)量,采用RevMan 5.3軟件進行數(shù)據(jù)統(tǒng)計分析。結(jié)果:最終納入6篇RCTs,總計10565例患者,其中EES組5913例,ZES組4652例。Meta分析結(jié)果顯示:接受EES和ZES治療的冠心病患者在全因死亡(RR=1.01,95%CI:0.85~1.20,P=0.91)、心源性死亡(RR=0.96,95%CI:0.76~1.21,P=0.73)、心肌梗死(RR=0.88,95%CI:0.75~1.02,P=0.10)、確定的和很可能的支架內(nèi)血栓(RR=0.79,95%CI:0.53~1.17,P=0.24)、主要不良心血管事件(RR=0.97,95%CI:0.86~1.09,P=0.59)、靶病變血運重建(RR=0.87,95%CI:0.72~1.03,P=0.11)、靶血管血運重建(RR=0.94,95%CI:0.81~1.10,P=0.47)、面向設備的復合終點(RR=0.95,95%CI:0.83~1.08,P=0.43)、面向患者的復合終點(RR=0.96,95%CI:0.88~1.06,P=0.43)等方面的差異均無統(tǒng)計學意義。結(jié)論:結(jié)果表明,EES和ZES在治療冠心病患者時安全性與有效性相當,但需要更多的大型隨機臨床試驗來進一步證實。
[Abstract]:Aim: to evaluate the safety and efficacy of Everolimus-eluting stentsEES and Zotarolimus-eluting stentsZESs in the treatment of coronary heart disease.Methods: a computer-based search was conducted on the Cochrane Library of PubMeda, VIPP, CNKIJ, CBMN, and Wanfang database, respectively. A randomized controlled trial was conducted to compare EES and ZES in the treatment of coronary heart disease (CHD) patients in a randomized controlled trial (Randomized controlled trialator).The data were evaluated and extracted by two evaluators, and the quality of the study was evaluated according to the Cochrane system evaluator manual (version 5.1.0). The data were analyzed by RevMan 5.3 software.Results: a total of 10565 patients were included in 6 RCTs.The results of meta-analysis of 4652 patients with coronary heart disease treated with EES and ZES in EES group (5913 cases) showed that the total death rate of patients with coronary heart disease was RR1.01C 1.01N 95 CI: 0.851.20 P0.91, RR0.961.21CI: 0.761.21P0.73, RRN 0.8895 CI: 0.751.02P0.100.The determined and probable intracardiac thrombus was RR0.7995CI0.530.97CI0.530.17P0.24N, and the main adverse cardiovascular events were found to be the main adverse cardiovascular events.Conclusion: the results suggest that the safety and efficacy of EES and ZES in the treatment of coronary heart disease patients are similar, but more large randomized clinical trials are needed to further confirm.
【學位授予單位】：廣西醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R541.4

【參考文獻】

中國期刊全文數(shù)據(jù)庫 前1條

1 曾憲濤;包翠萍;曹世義;劉菊英;;Meta分析系列之三:隨機對照試驗的質(zhì)量評價工具[J];中國循證心血管醫(yī)學雜志;2012年03期

，

本文編號：1746035